New Medical Device Rule Could Hit Costs and Export Flexibility

India’s new Medical Device Rule could increase compliance costs for manufacturers. The rule requires makers to disclose details of outsourced sterilization facilities on device labels. The medical device rule is aimed at improving traceability and transparency in the sector.

Under the new requirement, medical device manufacturers must mention the licence number of sterilization facilities used by subcontractors. This applies when sterilization is outsourced to another facility.

The move is expected to give regulators greater visibility into the sterilization process. It could also help trace devices back to the facilities involved in their processing.

However, medical device companies have raised concerns about the impact of the requirement. They say the change could add to compliance work and operating costs.

Key points of the new requirement include:

• Manufacturers must disclose the licence number of outsourced sterilization facilities.
• The details will have to appear on medical device labels.
• The rule is aimed at improving traceability across the supply chain.
• Companies may face additional compliance and labelling costs.

Why are medical device makers concerned?

Medical device manufacturers often rely on specialized third-party facilities for sterilization. These facilities process devices before they reach hospitals and other users. Industry players have reportedly flagged concerns over the additional labelling requirement. Changes to labels can involve fresh packaging material, approvals and inventory management.

The impact could be greater for companies that export medical devices. Different markets can have different labelling requirements. Manufacturers may need to manage separate packaging and labels for different markets.

This could reduce flexibility in production and increase the cost of maintaining multiple label versions. The industry is also concerned about how quickly companies can implement the change. Existing stocks and packaging may need to be handled carefully to avoid disruptions.

Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market

What could the rule mean for India’s medical device industry?

The government’s move comes as India works to strengthen regulation and oversight of its medical device sector. Better disclosure can improve accountability when sterilization is handled by third-party facilities. It can also make it easier to identify the facility involved if quality concerns emerge.

At the same time, manufacturers may need to adjust their compliance systems. Companies using several sterilization partners could face a larger administrative burden.

The rule could have several effects on the industry:

• Higher compliance and packaging expenses.
• More documentatioan for outsourced sterilization.
• Possible changes to existing product labels.
• Greater traceability of sterilization facilities.
• Potential challenges for export-oriented manufacturers.

For medical device companies, the key challenge will be balancing regulatory compliance with cost and operational flexibility.